A Study to Determine Number of Patients who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

Overview

About this study

The purpose of this study is to determine how many people develop high ammonia levels and to characterize risk factors for development of high ammonia levels after receiving recombinant Erwinia asparaginase.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Citeria:

Followed by pediatric hematology/oncology.
Receiving recombinant Erwinia asparaginase for treatment of malignancy.

Exclusion Criteria:

Patients < 1 year of age.
Patients who have previously received recombinant Erwinia asparaginase within the past two weeks.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/27/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Catherine Martin, Pharm.D., R.Ph.	Open for enrollment	Contact information: Cancer Center Clinical Trials Referral Office (855) 776-0015

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Catherine Martin, Pharm.D., R.Ph.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Clinical Trials